WuXi AppTec

WuXi AppTec (Stock Code: 603259.SH/2359.HK) provides integrated, end-to-end new drug research and development and production services to the global biopharmaceutical industry, with operational bases in Asia, Europe, North America, and other regions. Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers R&D barriers, helps customers improve R&D efficiency, and brings more breakthrough treatment solutions to patients. Its service scope covers areas such as chemical drug R&D and production, biological research, preclinical testing and clinical trial R&D, as well as cell and gene therapy R&D, testing, and production. In 2021, WuXi AppTec was rated ESG (Environmental, Social, and Governance) AA by MSCI. Currently, the company's enabling platform supports over 5,850 R&D innovation projects from partners in more than 30 countries worldwide, committed to bringing more new and better drugs to patients globally and realizing the vision of "making drugs easier to make and diseases easier to cure" as soon as possible.